Page 339 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 24 Complement and Immunoglobulin Biology Leading to Clinical Translation 281

TABLE Monoclonal Antibodies Approved by the FDA as Therapies—cont’d
24.4
Year Route of
Generic Name Trade Name Target Source Approved Indication Administration
Ustekinumab Stelara IL-12/23 Human 2009 Psoriatic arthritis, plaque Subcutaneous
psoriasis
Ofatumumab Arzerra CD20 Human 2009 CLL Intravenous
Denosumab Prolia/Xgeva RANK-L Human 2010 Bone metastases, Subcutaneous
osteoporosis
Tocilizumab Actemra IL-6 receptor Humanized 2010 Rheumatoid arthritis, Intravenous
systemic juvenile
idiopathic arthritis
Bretuximab Adcetris CD30 Chimeric conjugate 2011 Hodgkin, anaplastic large Intravenous
vedotin cell lymphoma
Belimumab Benlysta BLyS Human 2011 Systemic lupus Intravenous
Ipilimumab Yervoy CTLA-4 Human 2011 Melanoma Intravenous
Raxibacumab From CDC Anthrax protective Human 2012 Inhalational anthrax Intravenous
antigen
Pertuzumab Perjeta HER2 Humanized 2012 Breast cancer Intravenous
Obinutuzumab Gazyva CD20 Humanized 2013 CLL Intravenous
Ado trastuzumab Kadcyla HER2 Humanized, 2013 Breast cancer Intravenous
emtansine conjugated
Nivolumab Opdivo PD1 Human 2014 Melanoma, lung cancer Intravenous
Blinatumomab Blincyto CD19; CD3 Mouse 2014 ALL Intravenous
continuous
infusion
Pembrolizumab Keytruda PD1 Humanized 2014 Melanoma Intravenous
Ramucirumab Cyramza VEGFR2 Human 2014 Gastric, GE junction, and Intravenous
lung cancer
Vedolizumab Entyvio α4β7 integrin Humanized 2014 Crohn disease, ulcerative Intravenous
colitis
Siltuximab Sylvant IL-6 Chimeric 2014 Multicentric Castleman Intravenous
disease
Dinutuximab Unituxin Ganglioside GD2 Chimeric 2015 Neuroblastoma Intravenous
Evolocumab Repatha PCSK9 Human 2015 Hypercholesterolemia Subcutaneous
Idarucizumab Praxbind Dabigatran Humanized Fab 2015 Reversal of anticoagulation Intravenous
effect of dabigatran
Alirocumab Praluent PCSK9 Human 2015 Hypercholesterolemia Subcutaneous
Necitumumab Portrazza EGFR Human 2015 Squamous non-small cell Intravenous
lung cancer
Mepolizumab Nucala IL-5 Humanized 2015 Asthma Subcutaneous
Daratumumab Darzalex CD38 Human 2015 Myeloma Intravenous
Secukinumab Consentyx IL-17a Human 2015 Plaque psoriasis, psoriatic Subcutaneous
arthritis, ankylosing
spondylitis
Elotuzumab Empliciti SLAMF7 Humanized 2015 Myeloma Intravenous
Ixekizumab Taltz IL-17 Humanized 2016 Psoriasis Subcutaneous
Reslizumab Cinqair IL-5 Humanized 2016 Asthma with eosinophilic Intravenous
phenotype
Obiltoxaximab Anthim Anthrax protective Humanized 2016 Inhalational anthrax Intravenous
antigen
aHUS, Atypical hemolytic uremic syndrome; AMD, age-related macular degeneration; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic
lymphocytic leukemia; EGFR, epidermal growth factor receptor; GE, gastroesophageal; IL, interleukin; PNH, paroxysmal nocturnal hemoglobinuria; RSV, respiratory
syncytial virus; TNF, tumor necrosis factor.